Taisho Pharmaceutical Co., Ltd.

Nissan Chemical Industries Limited

Shusei Ito

Mari Nakano

Kenji Yamada

Akio Miwa

Noriyuki Hirasawa

Akihiko Tasaki

Nobuyoshi Kamikido

Ayumi Koda

Disclosed is a sustained release preparation which releases a poorly soluble medicinal agent in a pH-independent manner. Also disclosed is a sustained release preparation which is capable of controlling the Cof a medicinal agent to an adequate amount and is thus capable of maintaining the level of the medicinal agent in the blood to a level at which medicinal effects can be expected for a long period of time. Specifically disclosed is a sustained release preparation which is characterized by containing a pharmaceutically acceptable salt of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, and hypromellose. An organic acid is blended in the sustained release preparation in an amount of less than 1% by mass.

Extended release preparation

The present invention provides a pharmaceutical composition comprising N-(3-chloro-4-morpholin-4-yl)phenyl-N&prime;-hydroxyimidoformamidine and sulfobutyl ether &bgr;-cyclodextrin or a salt thereof, wherein sulfobutyl ether &bgr;-cyclodextrin increases the solubility of N-(3-chloro-4-morpholin-4-yl)phenyl-N&prime;-hydroxyimidoformamidine and improves the photostability.

Pharmaceutical composition

Preparation for nasal administration

Growing community of inventors

Tokyo, Japan

Shusei Ito